secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0002007919-25-000094
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx reports Q3 net loss $35.3M; ozekibart meets primary endpoint in chondrosarcoma
--------------------------------------------------------------------------------

- Net loss of $35.3M ($2.28 per share) vs $43.9M ($2.84) in Q3 2024; R&D expense down to $28.5M.
- Cash and equivalents $153.1M at Sept 30, 2025, down from $186.6M at June 30, 2025.
- Ozekibart (INBRX-109) met primary endpoint in registrational chondrosarcoma trial, showing statistically significant PFS improvement.
- Plan to submit BLA to FDA in Q2 2026; expansion cohorts in colorectal cancer and Ewing sarcoma show high response rates.
- $100M debt outstanding; interest expense of $3.2M in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/0002007919-25-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/inhibrx-20251114.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer